Moleculin Biotech (MBRX) Change in Account Payables (2016 - 2025)

Moleculin Biotech's Change in Account Payables history runs 10 years deep, the most recent figure standing at $1.3 million for Q4 2025.

• In Q4 2025, Change in Account Payables rose 347.5% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.3 million (up 384.19% YoY), while the FY2025 annual figure was $1.3 million, up 384.19% from the prior year.
• Change in Account Payables for Q4 2025 stood at $1.3 million, up from -$1.5 million in the prior quarter.
• The five-year high for Change in Account Payables was $2.2 million in Q2 2023, with the low at -$2.1 million in Q3 2023.
• The 5-year median for Change in Account Payables is $179000.0 (2021), against an average of $111550.0.
• Peak annual rise in Change in Account Payables reached 433.91% in 2022, while the deepest fall reached 5565.38% in 2022.
• Moleculin Biotech's Change in Account Payables stood at -$26000.0 in 2021, then slumped by 5565.38% to -$1.5 million in 2022, then surged by 133.27% to $490000.0 in 2023, then tumbled by 206.12% to -$520000.0 in 2024, then soared by 347.5% to $1.3 million in 2025.
• Business Quant data shows MBRX's Change in Account Payables at $1.3 million in Q4 2025, -$1.5 million in Q3 2025, and $850000.0 in Q2 2025.